Going global? Chinese biotechs face a big challenge – MRCT

By Wang Fangqing

A lot of topics were discussed at the 2023 China innovative medicine (device) medical conference (CMAC) held in Suzhou on April 7. Among them were real world studies, medical affairs and how to use AI to speed up discoveries. But one most talked about was the challenges for Chinese biotechs to go global.

Under the great pressure of severe domestic competition over biosimilars and fast-follow drugs, as well as the national drug purchasing scheme that drastically reduced return on investment, Chinese biotechs are eager to see their drugs sold outside China. But one big challenge is doing multi-regional clinical trials (MRCT).